Johnson & Johnson Halts Development of IL-4Rα/IL-31 Bispecific Antibody JNJ-5939 Following Disappointing Phase 2b Trial in Atopic Dermatitis

December 26, Johnson & JohnsonAnnouncing itsIL-4Rα/IL-31 Bispecific AntibodyJNJ-95475939（JNJ-5939）InResults from the planned interim analysis of the Phase 2b DUPLEX-AD proof-of-concept study (95475939ADM2001) in moderate to severe atopic dermatitis (AD) met the pre-defined criteria for early termination as they did not meet the high bar for efficacy we have set to advance our clinical development program in atopic dermatitis. JNJ-5939 was well tolerated in the study.

Johnson & Johnson is firmly committed to advancing the development of our robust portfolio of clinical-stage and preclinical candidates for atopic dermatitis. Atopic dermatitis is a chronic and often debilitating disease with significant unmet needs, imposing both physical and emotional burdens on patients and their families. We look forward to delivering the most promising novel transformative therapies to meet the needs of more than 100 million people worldwide affected by this condition.

In May 2024, Johnson & Johnson acquired for $1.25 billionNumab TherapeuticsThe wholly-owned subsidiary Yellow Jersey Therapeutics (YJT), thereby gainingWill enter Phase 2 clinical developmentNM26（JNJ-5939）。This bispecific antibody was discovered and designed using Numab's proprietary MATCH™ technology platform.Targeting IL-4Rα (Type I and Type II receptors) and IL-31。（$1.25 Billion! Johnson & Johnson Acquires YJT, Obtains an IL-4Rα/IL-31 Bispecific Antibody）